Navigation Links
MGT Capital Investments, Inc. is Delighted with the Announcement of Medicsight's Commercial Agreement with Toshiba PACS Division
Date:2/13/2008

Medicsight and Toshiba PACS division sign commercial agreement

NEW YORK, Feb. 13 /PRNewswire-FirstCall/ -- Medicsight PLC is pleased to announce that it has signed a preliminary agreement with the System Integration division of Toshiba Medical Systems Corporation ("Toshiba") for the resale of its MedicRead Colon and ColonCAD software solutions throughout Japan.

Toshiba Medical Systems Corp. is a global leading provider of diagnostic medical imaging systems and comprehensive medical solutions, such as CT, X- ray, Ultrasound, Nuclear Medicine, MRI and information systems. Toshiba will work with Medicsight to obtain MHLW approval in Japan. In addition, both companies have also identified the need for radiologists and gastroenterologists to be trained in the use of the software to help them to interpret CT colonography (CTC) images and rapidly identify suspicious regions for detailed evaluation. In late October Medicsight and Toshiba hosted CTC training workshops at the Japanese Digestive Disease Week (JDDW) conference in Kobe. The JDDW conference is the largest Gastroenterological congress of the year in Japan. Medicsight and Toshiba will continue to work together on similar market development initiatives in 2008 and beyond.

David Sumner, Chief Executive of Medicsight, commented: "We are delighted to be working with Toshiba, one of the world's largest medical imaging solution providers. This agreement is timely as the recently announced positive outcomes of two major clinical trials are widely expected to accelerate the adoption of CTC (also known as virtual colonoscopy) as routine primary screening for colorectal cancer. Toshiba will help to promote the use of our MedicRead Colon and ColonCAD(TM) software to ease the workload of radiologists and to help them accurately identify colorectal polyps and tumors at an early stage when there is a good chance of successful treatment. We see this as bringing important benefits to both Japanese patients and the Japanese healthcare system alike."

Takashi Masuzawa, Chief Specialist of Toshiba System Integration development department, added: "We believe that the Medicsight advanced software solutions will augment the strong portfolio of Toshiba products and provide an opportunity to market the integrated PACS products to current and future customers. Both Medicsight and Toshiba view this agreement as the start of a long term relationship for CT colonography solution in Japan. It is the intent of this agreement to continue further development and licensing of joint Medicsight and Toshiba products through the Toshiba PACS channel."

Gen Iinuma, Head of Staffs, Diagnostic Radiology Division, National Cancer Center Hospital Tokyo, commented: "We have been working on the development of the Medicsight ColonCAD in collaboration with Professor Steve Halligan, University College Hospital, for some time now. This collaboration consists of a 3 year clinical programme, which when delivered upon will deliver 8 clinical studies to support both the regulatory and sales & marketing efforts of Medicsight and Toshiba. We have been delighted with the performance of the product and are very pleased that the Radiology community at large will soon have this additional software solution available to them to help combat this debilitating and potentially fatal disease."

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc. (Amex: MGT) is a holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.

Medicsight PLC is a UK headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's computer-aided detection (CAD) software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at http://www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.


'/>"/>
SOURCE MGT Capital Investments, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Roth Capital Partners 20th Annual OC Conference
2. Genstar Capital Promotes J. Ryan Clark to Principal
3. MGT Capital Investments, Inc. Announces Subsidiarys Preliminary Agreement to Acquire Maydeal.com
4. 19th Annual Casino Night Benefiting the National Kidney Foundation of the National Capital Area
5. Pennsylvania Gov. Rendell: $10 Million Partnership With Harrisburg Venture Capital Firm Boosts PAs Life Sciences Industry
6. IDC Awarded Digital Radiography Contract With Beijing Capital Airport
7. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
8. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
9. Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients
10. Capital BlueCross CEO Says Meaningful Statewide Competition Must Be Key Criteria in Pennsylvanias Review of Proposed Highmark-IBC Merger
11. Asthma Foundation Announces 2008 Asthma Capitals, Knoxville on Top Again
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: